Drug intelligence / Profile preview

IVIG + Anti-Pathogen Hyperimmune

Development stage: Preclinical
Lead developer: Grifols
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

GigaGen, a subsidiary of Grifols, is developing a recombinant polyclonal intravenous immunoglobulin (IVIG) therapeutic for the treatment of immunodeficiencies. This biologic therapy is engineered to provide broad-spectrum antibodies against multiple common disease pathogens, offering passive immunity to patients with primary immunodeficiency diseases whose immune systems are unable to produce adequate antibody levels. Utilizing a proprietary single-cell technology, GigaGen captures and recreates complete antibody repertoires from human donors to generate immortalized DNA libraries. This approach enables the consistent, scalable manufacturing of recombinant polyclonal products, overcoming the limitations of traditional plasma-derived IVIG which relies on continuous donor collection.

Other names: recombinant polyclonal IVIGrecombinant polyclonal immunoglobulinintravenous immunoglobulin + anti-pathogen hyperimmune globulin

Targets

HBsAg (Hepatitis B surface antigen)SARS-CoV-2 spike

Beyond the preview

Go deeper on IVIG + Anti-Pathogen Hyperimmune.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVIG + Anti-Pathogen Hyperimmune.

Explore the full profile